Non-Small Cell Lung Cancer
Conditions
Brief summary
This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).
Detailed description
This is a multicenter, open-label, Phase II clinical study to evaluate the efficacy, safety, tolerability, PK characteristics, and immunogenicity of SKB571Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC). Approximately 150 subjects will be enrolled in this study, including 3 cohorts.
Interventions
Intravenous(IV) infusion(Q3W)
DRUGOsimertinib
orally once daily
DRUGFurmonertinib
orally once daily
DRUGcarboplatin
Intravenous(IV) infusion(Q3W)
DRUGCisplatin
Intravenous(IV) infusion(Q3W)
DRUGPembrolizumab
Intravenous(IV) infusion(Q3W)
Sponsors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form (ICF). 2. Participants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC). 3. At least one measurable lesion as assessed by the investigator according to RECIST v1.1. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. Life expectancy ≥ 12 weeks as assessed by the investigator. 6. Adequate organ and bone marrow function. 7. Male and female participants must agree to use highly effective methods of contraception during the study treatment period. 8. Participants must voluntarily join this study, sign the ICF, and be able to comply with the visits and related procedures specified in the protocol.
Exclusion criteria
1. Participants with other malignant tumors within 3 years before the first dose of study treatment. 2. Active or untreated central nervous system (CNS) metastasis. 3. Current uncontrolled concomitant diseases 4. Clinically severe lung damage due to complications of lung disorder 5. Participants with a history of interstitial lung disease (ILD)/non-infectious pneumonitis 6. A history of severe skin diseases 7. Unresolved toxicity from prior anti-tumor therapy 8. Serious infection within 4 weeks before the first dose of study treatment 9. Known active pulmonary tuberculosis. 10. Participants who have undergone major surgery or had severe trauma within 4 weeks before the first dose, or are expected to require major surgery during the study. 11. Known history of allogeneic organ transplant or allogeneic hematopoietic stem cell transplant. 12. Pregnant or breastfeeding women. 13. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR) | Up to approximately 36 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS), duration of response (DOR), disease control rate (DCR), and overall survival (OS) | Up to approximately 36 months | — |
| Safety and tolerability | Up to approximately 36 months | Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (based on CTCAE v6.0), clinically significant abnormal laboratory test results, etc. |
| Maximum Plasma Concentration (Cmax) of SKB571-ADC | Up to approximately 36 months | Blood Samples will be collected to determine the Cmax of SKB571-ADC in the plasma |
| Immunogenicity | Up to approximately 36 months | Blood Samples will be collected to measure Anti-drug antibody (ADA) against SKB571 in the serum |
| Minimum Plasma Concentration(Cmin) of SKB571-ADC | Up to approximately 36 months | Blood samples will be collected to determine the Cmin of SKB571-ADC in the plasma |
| Maximum Plasma Concentration(Cmax) of SKB571-TAb | Up to approximately 36 months | Blood samples will be collected to determine the Cmax of SKB571-TAb in the plasma |
| Minimum Plasma Concentration(Cmin) of SKB571-TAb | Up to approximately 36 months | Blood Samples will be collected to determine the Cmin of SKB571-TAb in the plasma |
| Maximum Plasma Concentration (Cmax) of unconjugated KL610348 | Up to approximately 36 months | Blood Samples will be collected to determine the Cmax of unconjugated KL610348 in the plasma |
| Minimum Plasma Concentration(Cmin) of unconjugated KL610348 | Up to approximately 36 months | Blood Samples will be collected to determine the Cmin of unconjugated KL610348 in the plasma |
Countries
China
Contacts
CONTACTXin Li, MD
STUDY_DIRECTORXin Li, MD
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Outcome results
None listed